- Home
- SEDG vs AUPH Comparison
SEDG vs AUPH Comparison
Compare SEDG & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEDG
- AUPH
- Stock Information
- Founded
- SEDG 2006
- AUPH 1993
- Country
- SEDG Israel
- AUPH Canada
- Employees
- SEDG N/A
- AUPH N/A
- Industry
- SEDG Semiconductors
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SEDG Technology
- AUPH Health Care
- Exchange
- SEDG Nasdaq
- AUPH Nasdaq
- Market Cap
- SEDG 1.5B
- AUPH 1.4B
- IPO Year
- SEDG 2015
- AUPH 1999
- Fundamental
- Price
- SEDG $36.18
- AUPH $11.74
- Analyst Decision
- SEDG Sell
- AUPH Strong Buy
- Analyst Count
- SEDG 21
- AUPH 2
- Target Price
- SEDG $19.32
- AUPH $13.00
- AVG Volume (30 Days)
- SEDG 3.7M
- AUPH 1.9M
- Earning Date
- SEDG 11-05-2025
- AUPH 11-06-2025
- Dividend Yield
- SEDG N/A
- AUPH N/A
- EPS Growth
- SEDG N/A
- AUPH N/A
- EPS
- SEDG N/A
- AUPH 0.42
- Revenue
- SEDG $940,561,000.00
- AUPH $260,111,000.00
- Revenue This Year
- SEDG $34.34
- AUPH $17.33
- Revenue Next Year
- SEDG $19.74
- AUPH $14.31
- P/E Ratio
- SEDG N/A
- AUPH $27.86
- Revenue Growth
- SEDG N/A
- AUPH 25.59
- 52 Week Low
- SEDG $10.24
- AUPH $6.55
- 52 Week High
- SEDG $40.50
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- SEDG 54.33
- AUPH 46.50
- Support Level
- SEDG $35.50
- AUPH $11.18
- Resistance Level
- SEDG $39.44
- AUPH $11.70
- Average True Range (ATR)
- SEDG 2.51
- AUPH 0.66
- MACD
- SEDG -0.23
- AUPH -0.18
- Stochastic Oscillator
- SEDG 44.58
- AUPH 42.50
About SEDG SolarEdge Technologies Inc.
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.